PMA Supplement Types
FDA submission mechanisms for changes to PMA-approved devices, selected according to the change and evidence required.
Definition
PMA change mechanisms include panel-track supplements for significant design or performance changes or new indications requiring substantial clinical data; 180-day supplements for changes supported primarily by preclinical data, sometimes with confirmatory clinical data; real-time supplements for eligible minor changes; Special PMA Supplements, Changes Being Effected, for specified safety-enhancing changes; and 30-day notices for eligible manufacturing-method or process changes affecting safety or effectiveness. FDA may convert an inadequate 30-day notice to a 135-day supplement. Site-change supplements and changes reportable in periodic reports must also be considered. Panel-track does not mean an advisory panel meeting is always required.What this means in practice
PMA change mechanisms include panel-track supplements for significant design or performance changes or new indications requiring substantial clinical data; 180-day supplements for changes supported primarily by preclinical data, sometimes with confirmatory clinical data; real-time supplements for eligible minor changes; Special PMA Supplements, Changes Being Effected, for specified safety-enhancing changes; and 30-day notices for eligible manufacturing-method or process changes affecting safety or effectiveness. FDA may convert an inadequate 30-day notice to a 135-day supplement. Site-change supplements and changes reportable in periodic reports must also be considered. Panel-track does not mean an advisory panel meeting is always required.Examples
- Illustrative: A manufacturer submits a Panel-Track Supplement when redesigning a critical component of a cardiac implant, as this change significantly impacts the device's safety and effectiveness and may require new clinical data.
- Hypothetical: a proposed sterilization-method change requires a documented regulatory assessment and appropriate validation evidence before implementation; consult FDA’s supplement decision guidance to select the route.
- Illustrative: A company changing the lubricant used in a manufacturing step, where the new lubricant is chemically similar and does not contact the final product, might qualify for a 30-Day Notice if all specific eligibility criteria are met.
- •Evaluate eligibility for a 30-day notice rather than defaulting to a 180-day supplement; review time and conversion depend on the submission.
- •Treating Special PMA Supplements (CBE) as universally applicable, they are restricted to specific change types defined in 21 CFR 814.39(d).
- •Letting changes accumulate into an annual report when individually they crossed the supplement threshold.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsPMA submission strategy where a manufacturer submits portions of the PMA (modules) sequentially as they become ready, rather than as a single complete application.
FDA's most stringent device marketing application, required for high-risk Class III devices.
Expedited PMA supplement review pathway where FDA and the manufacturer meet to review minor device or labeling changes in real time.
Yearly report required for Class III PMA devices summarizing changes, complaints, and post-approval study status.
More in Regulatory
· Same categoryFDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.
Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.
510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.
Where this term appears across MedTech Terms.
Sources
5 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Official-source claim check:
Selection depends on change and supporting evidence; 30-day notices may convert to 135-day supplements, and Special supplements are limited safety-enhancing changes.
Partial review: verified corrections are applied, but this is not a full accuracy certification. The last full review date is unchanged.
Remaining verification limits
- Original merged record reviewed in full. Illustrative examples are hypothetical, not verified case histories. Evidence supports the specific propositions below, not an assertion that every linked page verifies all merged content.
- 121 CFR 814.39 - PMA SupplementsTier 1 VerifiedeCFRecfr.gov
- 2Modifications to Devices Subject to PMA GuidanceTier 2 VerifiedFDAfda.gov
- 3IMDRF DocumentsTier 2 VerifiedIMDRFimdrf.org
- 4FDA supplement decision guidanceTier 2 UncheckedFDAfda.gov
- 5FDA supplements and amendmentsTier 2 UncheckedFDAfda.gov
Inline markers like [1] jump to the matching reference above.